-- 西太平洋银行-墨尔本研究所周二发布的报告显示,澳大利亚3月份消费者信心指数“暴跌”,创下新冠疫情爆发以来最大单月跌幅,并跌至2023年以来的最低水平。 该研究所表示,受燃油价格上涨和利率上升的双重打击,西太平洋银行-墨尔本研究所4月份消费者信心指数从3月份的91.6降至80.1。 该研究所指出,4月份“美国和以色列对伊朗发动战争后燃油价格飙升,以及澳大利亚储备银行再次加息25个基点,再次给消费者的财务状况带来巨大压力”。 澳大利亚消费者信心指数高于100表明消费者乐观,低于100则表明消费者悲观。 根据该研究所的月度调查,4月份澳大利亚消费者对失业的担忧升至近六年来的最高水平,同时消费者对房价前景的乐观程度也大幅下降。 西太平洋银行墨尔本研究所表示,澳大利亚消费者信心指数自2022年以来总体呈上升趋势,但目前已回落至历史低点附近,“尽管高于新冠疫情爆发初期以及上世纪八九十年代初经济衰退期间的极端水平”。 4月份“购买大型家用物品时机”分项指数从3月份的98降至83.3,这进一步表明消费者信心正在减弱。 4月份家庭预期也恶化。该研究所报告称:“消费者对经济和家庭财务的短期预期也急剧下降,表明他们认为经济前景黯淡,并正在为更多困难做好准备。” 西太平洋银行墨尔本研究所消费者信心调查每月对约1200名澳大利亚成年消费者(或家庭)进行调查。
Related Articles
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.